AstraZeneca Plc Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 7/10/2026)
| Balance Sheet | Total Assets | 97,125,569,524.00 | ROE | 28.47 % |
| Balance Sheet | Total Equity | 41,436,349,142.00 | ROA | 0.50 % |
| Cashflow | Capital Expenditures | -5,027,670,530.00 | P/FCF | 30.91 |
| Cashflow | Free Cash Flow | 7,381,863,420.00 | – | – |
| Cashflow | Operating Cash Flow | 12,409,533,950.00 | P/CF | 18.39 |
| Income | Earnings per Share (diluted) | 6.54 | Div. Yield | 1.86 % |
| Income | Net Income | 483,173,612.66 | P/E | 470.97 |
| Income | Shares Outstanding | 1,563,000,000.00 | P/B | 8.25 |
| Income | Total Revenue | 2,775,661,108.45 | P/S | 82.21 |
Ratios calculated on: 10/14/2026
Company Description
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.astrazeneca.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more